GLP-1-based strategies: a physiological analysis of differential mode of action (Q26997149)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

review article

1 reference

title

GLP-1-based strategies: a physiological analysis of differential mode of action (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Rémy Burcelin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Stéphane Dalle

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

1 reference

1 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

29

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

108-121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

2

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Convergence of hepatoportal glucose-sensitive afferent signals to glucose-sensitive units within the nucleus of the solitary tract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Critical role for peptide YY in protein-mediated satiation and body-weight regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The gut-brain axis: a major glucoregulatory player

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Pancreatic alpha-cell dysfunction in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

GLP-1, the gut-brain, and brain-periphery axes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The incretin concept today

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Circulation and degradation of GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The recombinant rat glucagon-like peptide-1 receptor, expressed in an alpha-cell line, is coupled to adenylyl cyclase activation and intracellular calcium release

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Role of the glucagon-like-peptide-1 receptor in the control of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Novel glucosensor for hypoglycemic detection localized to the portal vein

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Neuroprotective properties of GLP-1: theoretical and practical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic α-cells in mouse models of ß-cell regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Ghrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Developmental patterns of glucagon-like peptide-1-(7-36) amide and peptide-YY in rat pancreas and gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Effect of hepatic denervation on peripheral insulin sensitivity in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucose-sensitive afferent nerve fibers in the liver and their role in food intake and blood glucose regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Visceral afferents and metabolic function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

A new Alzheimer's disease interventive strategy: GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucose-sensing in glucagon-like peptide-1-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucose sensing in L cells: a primary cell study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon-like peptide-1 of brainstem origin activates dorsomedial hypothalamic neurons in satiated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Diabetic neuropathy--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The loss of GLUT2 expression by glucose-unresponsive beta cells of db/db mice is reversible and is induced by the diabetic environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Intestinal sensing of nutrients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Expression of the GLP-1 receptor in mouse, rat, and human pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon physiology and pathophysiology in the light of new advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The Role of Glucagon in the Endogenous Hyperglycemia of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sita

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: its structure and functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00009.2013

10.1152/PHYSIOL.00009.2013

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json

release_sivvkrtuozgxxi5f6o3marxgia

9 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sivvkrtuozgxxi5f6o3marxgia

mapped directly with Wikidata item

24 November 2022

based on heuristic

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583767%20AND%20SRC:MED&resulttype=core&format=json